This Market Spotlight report covers the Uterine Cancer market, comprising key marketed and pipeline drugs, clinical trials, recent events and analyst opinion, upcoming and regulatory events, probability of success, a 10-year disease incidence and prevalence forecast, and licensing and acquisition deals, as well as presenting drug-specific revenue forecasts.

Key Takeaways

• Datamonitor Healthcare estimates that in 2019, there were 385,200 incident cases of uterine cancer in females worldwide, and expects that number to increase to 404,300 incident cases by 2028.
• In the same year, there were an estimated 1.3 million five-year prevalent cases of uterine cancer worldwide, which is expected to increase slightly to 1.4 million cases by 2028.
• GlaxoSmithKline’s Jemperli, Merck & Co’s Keytruda, and Eisai’s Lenvima are the only FDA-approved drugs for uterine cancer. These drugs are administered via the intravenous and oral routes.
• The majority of industry-sponsored drugs in active clinical development for uterine cancer are in Phase II, with only one drug in Phase III.
• Therapies in active clinical development for uterine cancer focus on a wide variety of targets. These drugs are administered via the oral and intravenous routes.
• High-impact upcoming events for drugs in the uterine cancer space comprise topline Phase III trial results for Xpovio and Jemperli.
• The overall likelihood of approval of a Phase I solid tumors asset is 5.4%, and the average probability a drug advances from Phase III is 42.5%. Drugs, on average, take 9.9 years from Phase I to approval, compared to 9.8 years in the overall oncology space.
• The distribution of clinical trials across Phase I–IV indicates that the vast majority of trials for uterine neoplasms have been in the early and mid-phases of development, with 96% of trials in Phase I–II, and only 4% in Phase III–IV.
• The US has a substantial lead in the number of uterine neoplasms clinical trials globally. Spain and the UK lead the major European markets, while China, South Korea, and Thailand share the top spot in Asia.
• Clinical trial activity in the uterine neoplasms space is dominated by completed trials. Sanofi has the highest number of completed clinical trials for uterine neoplasms, with five trials.
• AstraZeneca, Merck & Co, and Sanofi lead the industry sponsors with the highest overall number of clinical trials for uterine neoplasms